Relationship between bilirubin, apolipoprotein B, and coronary artery disease

Lipoprotein lipids and apo B from 254 male patients were compared with bilirubin as a risk factor for coronary artery disease (CAD). Patients were classified as: 1, Normal, all vessels < 20% stenosis, n = 83; or 2, CAD, at least one vessel > 70%, n = 171. Diagnostic accuracy was assessed by receiver operator characteristic curves (ROC). Corrections were made for possible confounding variables in the multivariate analysis. Upon ROC analysis, bilirubin showed an inverse relationship with risk of CAD, with areas under the ROC curve comparable to lipoprotein: however, bilirubin showed no discrimination below false positive frequencies of approximately 0.3. Logistic regression indicated that bilirubin was a weaker global marker than the lipoproteins and interacted with apo B. A highly significant correlation was found between bilirubin and apo B (p = 0.0025), but not with cholesterol, triglycerides, or high density lipoprotein cholesterol. Compared to lipoprotein markers, bilirubin provides little practical power of discrimination for CAD. Further studies of the affect of bilirubin on CAD must take its interaction with apo B into consideration.

This article has been cited by other articles:

				B. Rantner, B. Kollerits, M. Anderwald-Stadler, P. Klein-Weigel, I. Gruber, A. Gehringer, M. Haak, M. Schnapka-Kopf, G. Fraedrich, and F. Kronenberg Association between the UGT1A1 TA-Repeat Polymorphism and Bilirubin Concentration in Patients with Intermittent Claudication: Results from the CAVASIC Study Clin. Chem., May 1, 2008; 54(5): 851 - 857. [Abstract] [Full Text] [PDF]

				J.-P. Lin, C. J. O'Donnell, J. P. Schwaiger, L. A. Cupples, A. Lingenhel, S. C. Hunt, S. Yang, and F. Kronenberg Association Between the UGT1A1*28 Allele, Bilirubin Levels, and Coronary Heart Disease in the Framingham Heart Study Circulation, October 3, 2006; 114(14): 1476 - 1481. [Abstract] [Full Text] [PDF]

				H. Wang, S. S. Lee, C. Dell'Agnello, V. Tchipashvili, J. D'Avilla, E. Czismadia, B. Y. Chin, and F. H. Bach Bilirubin Can Induce Tolerance to Islet Allografts Endocrinology, February 1, 2006; 147(2): 762 - 768. [Abstract] [Full Text] [PDF]

				H. Gullu, D. Erdogan, D. Tok, S. Topcu, M. Caliskan, T. Ulus, and H. Muderrisoglu High Serum Bilirubin Concentrations Preserve Coronary Flow Reserve and Coronary Microvascular Functions Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2289 - 2294. [Abstract] [Full Text] [PDF]

				R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF]

				T. W. Sedlak and S. H. Snyder Bilirubin Benefits: Cellular Protection by a Biliverdin Reductase Antioxidant Cycle Pediatrics, June 1, 2004; 113(6): 1776 - 1782. [Full Text] [PDF]

				L. Novotny and L. Vitek Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies Experimental Biology and Medicine, May 1, 2003; 228(5): 568 - 571. [Abstract] [Full Text] [PDF]